Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 13 |
| List of Tables | 12 | 2 |
| List of Figures | 14 | 1 |
| Introduction | 15 | 1 |
| Global Markets Direct Report Coverage | 15 | 1 |
| Metastatic Pancreatic Cancer Overview | 16 | 1 |
| Therapeutics Development | 17 | 2 |
| Pipeline Products for Metastatic Pancreatic Cancer Overview | 17 | 1 |
| Pipeline Products for Metastatic Pancreatic Cancer Comparative Analysis | 18 | 1 |
| Metastatic Pancreatic Cancer Therapeutics under Development by Companies | 19 | 4 |
| Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes | 23 | 1 |
| Metastatic Pancreatic Cancer Pipeline Products Glance | 24 | 3 |
| Late Stage Products | 24 | 1 |
| Clinical Stage Products | 25 | 1 |
| Early Stage Products | 26 | 1 |
| Metastatic Pancreatic Cancer Products under Development by Companies | 27 | 5 |
| Metastatic Pancreatic Cancer Products under Investigation by Universities/Institutes | 32 | 1 |
| Metastatic Pancreatic Cancer Companies Involved in Therapeutics Development | 33 | 50 |
| AbbVie Inc | 33 | 1 |
| Aduro BioTech, Inc. | 34 | 1 |
| ArQule, Inc. | 35 | 1 |
| Array BioPharma Inc. | 36 | 1 |
| AstraZeneca Plc | 37 | 1 |
| Axcentua Pharmaceuticals AB | 38 | 1 |
| Berg LLC | 39 | 1 |
| BioLineRx, Ltd. | 40 | 1 |
| Bionomics Limited | 41 | 1 |
| Boehringer Ingelheim GmbH | 42 | 1 |
| Boston Biomedical, Inc. | 43 | 1 |
| Bristol-Myers Squibb Company | 44 | 1 |
| Celgene Corporation | 45 | 1 |
| Clovis Oncology, Inc. | 46 | 1 |
| Cornerstone Pharmaceuticals, Inc. | 47 | 1 |
| CrystalGenomics, Inc. | 48 | 1 |
| CTI BioPharma Corp. | 49 | 1 |
| CytRx Corporation | 50 | 1 |
| Daiichi Sankyo Company, Limited | 51 | 1 |
| Eleison Pharmaceuticals LLC | 52 | 1 |
| Eli Lilly and Company | 53 | 1 |
| Ensol Biosciences Inc. | 54 | 1 |
| Erytech Pharma SA | 55 | 1 |
| F. Hoffmann-La Roche Ltd. | 56 | 1 |
| Fountain Biopharma Inc. | 57 | 1 |
| Gilead Sciences, Inc. | 58 | 1 |
| GlaxoSmithKline Plc | 59 | 1 |
| Immodulon Therapeutics Ltd. | 60 | 1 |
| Incyte Corporation | 61 | 1 |
| MabVax Therapeutics Holdings, Inc. | 62 | 1 |
| Merck &Co., Inc. | 63 | 1 |
| Merrimack Pharmaceuticals, Inc. | 64 | 1 |
| NanoCarrier Co., Ltd. | 65 | 1 |
| NantKwest, Inc. | 66 | 1 |
| Natco Pharma Limited | 67 | 1 |
| NewLink Genetics Corporation | 68 | 1 |
| Novartis AG | 69 | 1 |
| Oncolytics Biotech Inc. | 70 | 1 |
| Oncovir, Inc. | 71 | 1 |
| Oryx GmbH &Co. KG | 72 | 1 |
| Pfizer Inc. | 73 | 1 |
| Pharmacyclics, Inc. | 74 | 1 |
| Phoenix Biotechnology, Inc. | 75 | 1 |
| Precision Biologics, Inc. | 76 | 1 |
| Rexahn Pharmaceuticals, Inc. | 77 | 1 |
| Silence Therapeutics Plc | 78 | 1 |
| Targovax ASA | 79 | 1 |
| Tiltan Pharma Ltd. | 80 | 1 |
| Tocagen Inc. | 81 | 1 |
| Zeria Pharmaceutical Co., Ltd. | 82 | 1 |
| Metastatic Pancreatic Cancer Therapeutics Assessment | 83 | 18 |
| Assessment by Monotherapy Products | 83 | 1 |
| Assessment by Combination Products | 84 | 1 |
| Assessment by Target | 85 | 6 |
| Assessment by Mechanism of Action | 91 | 6 |
| Assessment by Route of Administration | 97 | 2 |
| Assessment by Molecule Type | 99 | 2 |
| Drug Profiles | 101 | 294 |
| (curcumin + gemcitabine hydrochloride + paclitaxel) Drug Profile | 101 | 1 |
| 5B1-ADC Drug Profile | 102 | 1 |
| acalabrutinib Drug Profile | 103 | 3 |
| aldoxorubicin hydrochloride Drug Profile | 106 | 14 |
| alpelisib Drug Profile | 120 | 3 |
| ARQ-761 Drug Profile | 123 | 1 |
| asparaginase Drug Profile | 124 | 7 |
| atezolizumab Drug Profile | 131 | 13 |
| Atu-027 Drug Profile | 144 | 4 |
| avasimibe Drug Profile | 148 | 1 |
| AXP-10711 Drug Profile | 149 | 2 |
| BI-853520 Drug Profile | 151 | 1 |
| binimetinib Drug Profile | 152 | 7 |
| BL-8040 Drug Profile | 159 | 10 |
| BNC-101 Drug Profile | 169 | 3 |
| Cellular Immunotherapy for Oncology Drug Profile | 172 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 173 | 1 |
| Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer Drug Profile | 174 | 2 |
| ceritinib Drug Profile | 176 | 5 |
| CG-200745 Drug Profile | 181 | 1 |
| Charis-1000 Drug Profile | 182 | 1 |
| CIM-1 Drug Profile | 183 | 1 |
| cisplatin Drug Profile | 184 | 2 |
| CPI-613 Drug Profile | 186 | 5 |
| dacomitinib Drug Profile | 191 | 3 |
| ensituximab Drug Profile | 194 | 4 |
| FB-704A Drug Profile | 198 | 1 |
| flucytosine ER + vocimagene amiretrorepvec Drug Profile | 199 | 7 |
| galunisertib Drug Profile | 206 | 3 |
| glufosfamide Drug Profile | 209 | 2 |
| GS-5745 Drug Profile | 211 | 2 |
| GSK-2256098 Drug Profile | 213 | 2 |
| haNK Program Drug Profile | 215 | 1 |
| HuMab-5B1 Drug Profile | 216 | 3 |
| ibrutinib Drug Profile | 219 | 25 |
| IMM-101 Drug Profile | 244 | 2 |
| INCB-52793 Drug Profile | 246 | 1 |
| indoximod Drug Profile | 247 | 5 |
| irinotecan hydrochloride Drug Profile | 252 | 11 |
| istiratumab Drug Profile | 263 | 2 |
| lapatinib ditosylate Drug Profile | 265 | 5 |
| LCL-161 Drug Profile | 270 | 2 |
| MesoCART Drug Profile | 272 | 1 |
| MK-2206 Drug Profile | 273 | 3 |
| MK-2206 + selumetinib sulfate Drug Profile | 276 | 1 |
| Monoclonal Antibody Conjugate to Target Mesothelin for Oncology Drug Profile | 277 | 2 |
| MVT-1075 Drug Profile | 279 | 1 |
| napabucasin Drug Profile | 280 | 6 |
| nimotuzumab Drug Profile | 286 | 4 |
| NRCAN-019 Drug Profile | 290 | 2 |
| olaparib Drug Profile | 292 | 9 |
| paclitaxel albumin bound Drug Profile | 301 | 8 |
| palbociclib Drug Profile | 309 | 10 |
| Parvoryx Drug Profile | 319 | 2 |
| PBI-05204 Drug Profile | 321 | 2 |
| PCI-27483 Drug Profile | 323 | 2 |
| pelareorep Drug Profile | 325 | 14 |
| PLX-7486 Drug Profile | 339 | 1 |
| Poly-ICLC Drug Profile | 340 | 3 |
| PRI-724 Drug Profile | 343 | 2 |
| RG-7876 Drug Profile | 345 | 1 |
| ribociclib succinate Drug Profile | 346 | 4 |
| rottlerin Drug Profile | 350 | 1 |
| rucaparib camsylate Drug Profile | 351 | 7 |
| RX-0201 Drug Profile | 358 | 4 |
| SGT-53 Drug Profile | 362 | 2 |
| Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer Drug Profile | 364 | 1 |
| sonidegib phosphate Drug Profile | 365 | 4 |
| TG-01 Drug Profile | 369 | 2 |
| TL-118 Drug Profile | 371 | 2 |
| tosedostat Drug Profile | 373 | 5 |
| trametinib dimethyl sulfoxide Drug Profile | 378 | 4 |
| ubidecarenone Drug Profile | 382 | 2 |
| ulixertinib Drug Profile | 384 | 1 |
| ulocuplumab Drug Profile | 385 | 2 |
| Vaccine for Oncology Drug Profile | 387 | 1 |
| veliparib Drug Profile | 388 | 6 |
| Z-360 Drug Profile | 394 | 1 |
| Metastatic Pancreatic Cancer Dormant Projects | 395 | 5 |
| Metastatic Pancreatic Cancer Discontinued Products | 400 | 3 |
| Metastatic Pancreatic Cancer Product Development Milestones | 403 | 12 |
| Featured News &Press Releases | 403 | 1 |
| Aug 04, 2016: Merrimack Provides Update on ONIVYDE | 403 | 1 |
| Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas | 403 | 1 |
| Jun 30, 2016: NAPOLI-1 Data Demonstrates ONIVYDE Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer | 404 | 1 |
| Jun 28, 2016: BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA (pembrolizumab) for Treatment of Pancreatic Cancer | 405 | 1 |
| Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer | 405 | 1 |
| Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer | 406 | 1 |
| Jun 07, 2016: Boston Biomedical Featured Clinical Posters on Cancer Stem Cell Pathway Inhibitor Napabucasin in Multiple Cancer Types at ASCO 2016 | 407 | 3 |
| Jun 03, 2016: NewLink Genetics to Present Data on Indoximod at American Society of Clinical Oncology (ASCO) Annual Meeting | 410 | 1 |
| May 19, 2016: Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drug Napabucasin in Multiple Cancer Types at ASCO 2016 | 411 | 1 |
| May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 | 411 | 1 |
| May 18, 2016: Merrimack to Present Data on ONIVYDE at the 2016 American Society of Clinical Oncology Annual Meeting | 412 | 1 |
| May 18, 2016: Boston Biomedical Announces Clinical Data on First-in-Class Investigational Cancer Stem Cell Pathway Inhibitor Napabucasin in Multiple Cancer Types at ASCO 2016 | 412 | 1 |
| May 16, 2016: MabVax Therapeutics HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer | 412 | 1 |
| Apr 14, 2016: Oncolytics Biotech Reports Updated Data from Randomized Phase 2 Study of REOLYSIN in Pancreatic Cancer | 413 | 1 |
| Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations | 414 | 1 |
| Appendix | 415 | 2 |
| Methodology | 415 | 1 |
| Coverage | 415 | 1 |
| Secondary Research | 415 | 1 |
| Primary Research | 415 | 1 |
| Expert Panel Validation | 415 | 1 |
| Contact Us | 415 | 1 |
| Disclaimer | 416 | 1 |